Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...
Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes ...
The Dow Jones rose Wednesday ahead of the Federal Reserve's favored inflation gauge. Nvidia stock extended its recent losses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback